Metabolic Solutions Development Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Metabolic Solutions Development Company
The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.
Although it is the first company to reach Phase III in non-alcoholic steatohepatitis, Intercept has a long road ahead with a 2,500-patient trial that will include a 72-week interim look that could lead to initial approval in the U.S. and EU.
The private US firm Metabolic Solutions Development Company (MSDC) has presented Phase IIb data for its insulin sensitiser drug candidate that it says has a novel metabolic action that should avoid the side-effects that have damaged the glitazone drug class.
Metabolic Solutions Development thinks it knows why diabetes drugs directed against PPAR-γ ran into safety problems. The start-up is leveraging insights about what not to do, as it works to create an insulin sensitizer that lowers blood glucose levels without increasing white fat and without causing dangerous side effects.